Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Dosage of CBD oil for Arthritis Pain

monoiodoacetate–induced 3.5. sodium Cannabidiol damage nerve prophylaxis peripheral and



  • monoiodoacetate–induced 3.5. sodium Cannabidiol damage nerve prophylaxis peripheral and
  • 1. Introduction
  • Cannabidiol prophylaxis and sodium monoiodoacetate–induced peripheral nerve. Cannabidiol prophylaxis and sodium monoiodoacetate–induced peripheral nerve damage. Treatment of OA knees with CBD during the acute inflammatory. Exposure to cannabidiol induced an intracellular Ca(2+) rise in optic nerve . (+)- CBD, but not the other analogues, stimulated VR1 with EC50= – μM, And persistent pain produced by peripheral tissue injury and inflammation rats ( g) by intra-articular injection of sodium monoiodoacetate (MIA; 3 mg).

    monoiodoacetate–induced 3.5. sodium Cannabidiol damage nerve prophylaxis peripheral and

    Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. Unfortunately, currently available therapeutic strategies do not provide adequate relief and some patients are treatment-resistant. In this regard, cannabidiol CBD , a non-psychoactive constituent of Cannabis sativa, has shown significant promise as a potential antipsychotic for the treatment of schizophrenia. However, there is still considerable uncertainty about the mechanism of action of CBD as well as the brain regions which are thought to mediate its putative antipsychotic effects.

    We argue that further research on CBD is required to fast-track its progress to the clinic and in doing so, we may generate novel insights into the neurobiology of schizophrenia. Cannabidiol in humans-the quest for therapeutic targets. Cannabidiol CBD , a major phytocannabinoid constituent of cannabis, is attracting growing attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties.

    However, up to this point, a comprehensive literature review of the effects of CBD in humans is lacking. The aim of the present systematic review is to examine the randomized and crossover studies that administered CBD to healthy controls and to clinical patients. Both monotherapy and combination studies e. A total of 34 studies were identified: Potential pharmacokinetic and pharmacodynamic explanations for these results are discussed.

    Abstract Cannabidiol CBD , a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties.

    It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid SGF is a highly artificial approach that deviates significantly from physiological conditions in the stomach; therefore, SGF does not allow an extrapolation to in vivo conditions.

    In addition, the typical spectrum of side effects of THC, or of the very similar synthetic cannabinoid nabilone, as listed in the official Summary of Product Characteristics e. Cannabidiol CBD , a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties.

    Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: Cannabis use and the development of schizophrenic psychoses share a variety of similarities. Both start during late adolescence; go along with neuropsychological deficits, reduced activity, motivation deficits, and hallucinations suggesting impairment of similar brain structures.

    In cannabis heavy users diminished regional gray and white matter volume was reported. Similar alterations were observed in the large literature addressing structural abnormalities in schizophrenia. Furthermore, in cannabis using schizophrenic patients, these brain alterations were especially pronounced. Close relatives of schizophrenic patients showed greater cannabis-associated brain tissue loss than non-relatives indicating a genetically mediated particular sensitivity to brain tissue loss.

    Possible mechanisms for the induction of structural brain alterations are here discussed including impairments of neurogenesis, disturbance of endocannabinoids and diminished neuroplasticity. Especially direct THC effects or via endocannabinoids may mediate diminished glutamatergic neurotransmission usually driving neuroplasticity. Correspondingly, alterations of the kynurenic acid blocking NMDA receptors may contribute to brain structure alterations.

    However, different cannabis compounds may exert opposite effects on the neuroanatomical changes underlying psychosis. This finding is further supported by several animal experiments supporting neuroprotective properties of CBD mainly via anti-oxidative effects, CB2 receptors or adenosine receptors. We will discuss here the mechanisms by which CBD may reduce brain volume loss, including antagonism of THC, interactions with endocannabinoids, and mechanisms that specifically underlie antipsychotic properties of CBD.

    Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl- cannabidiol - studies in BV-2 microglia and encephalitogenic T cells.

    The expression levels of selected genes involved in stress regulation and inflammation were determined by quantitative real-time PCR. DMH-CBD downregulates the expression of inflammatory cytokines and protects the microglial cells by inducing an adaptive cellular response against inflammatory stimuli and oxidative injury.

    Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Cannabidiol , the main nonpsychotropic constituent of Cannabis sativa, possesses a large number of pharmacological effects including anticonvulsive, sedative, hypnotic, anxiolytic, antipsychotic, anti-inflammatory, and neuroprotective, as demonstrated in clinical and preclinical studies.

    Many neurodegenerative disorders involve cognitive deficits, and this has led to interest in whether cannabidiol could be useful in the treatment of memory impairment associated to these diseases. We used an animal model of cognitive impairment induced by iron overload in order to test the effects of cannabidiol in memory-impaired rats. Rats received vehicle or iron at postnatal days At the age of 2 months, they received an acute intraperitoneal injection of vehicle or cannabidiol 5.

    In order to investigate the effects of chronic cannabidiol , iron-treated rats received daily intraperitoneal injections of cannabidiol for 14 days. Twenty-four hours after the last injection, they were submitted to object recognition training.

    Retention tests were performed 24 h after training. A single acute injection of cannabidiol at the highest dose was able to recover memory in iron-treated rats. Chronic cannabidiol improved recognition memory in iron-treated rats.

    Acute or chronic cannabidiol does not affect memory in control rats. The present findings provide evidence suggesting the potential use of cannabidiol for the treatment of cognitive decline associated with neurodegenerative disorders. Further studies, including clinical trials, are warranted to determine the usefulness of cannabidiol in humans suffering from neurodegenerative disorders.

    Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy.

    Acute alcohol drinking induces steatosis, and effective prevention of steatosis can protect liver from progressive damage caused by alcohol. Increased oxidative stress has been reported as one mechanism underlying alcohol-induced steatosis.

    We evaluated whether cannabidiol , which has been reported to function as an antioxidant, can protect the liver from alcohol-generated oxidative stress-induced steatosis. Cannabidiol can prevent acute alcohol-induced liver steatosis in mice, possibly by preventing the increase in oxidative stress and the activation of the JNK MAPK pathway. Importantly, cannabidiol can prevent the decrease in autophagy induced by alcohol. In conclusion, these results show that cannabidiol protects mouse liver from acute alcohol-induced steatosis through multiple mechanisms including attenuation of alcohol-mediated oxidative stress, prevention of JNK MAPK activation, and increasing autophagy.

    We have previously reported that cannabidiol CBD lowers the incidence of diabetes in young non-obese diabetes-prone NOD female mice. In the present study we show that administration of CBD to 11—14 week old female NOD mice, which are either in a latent diabetes stage or with initial symptoms of diabetes, ameliorates the manifestations of the disease.

    In addition, the level of the proinflammatory cytokine IL produced by splenocytes was significantly reduced, whereas the level of the anti-inflammatory IL was significantly elevated following CBD-treatment. Histological examination of the pancreata of CBD-treated mice revealed more intact islets than in the controls. Our data strengthen our previous assumption that CBD, known to be safe in man, can possibly be used as a therapeutic agent for treatment of type 1 diabetes.

    Accumulating evidence suggests that cannabidiol CBD may be an effective and safe anxiolytic agent and potentially also an antidepressant. The objective of this study was to further examine these properties of CBD using the 'depressive-like' Wistar-Kyoto WKY rat, focusing on the drug's effect on anhedonia-like behaviors. These findings extend the limited knowledge on the antidepressant effect of CBD, now shown for the first time in a genetic animal model of depression.

    These results suggest that CBD may be beneficial for the treatment of clinical depression and other states with prominent anhedonia. The astrocytes have gained in recent decades an enormous interest as a potential target for neurotherapies, due to their essential and pleiotropic roles in brain physiology and pathology. The cannabinoid system and its ligands have been shown to interact and affect activities of astrocytes.

    Cannabidiol CBD is the main non-psychotomimetic cannabinoid derived from Cannabis. Here, we attempt to sum up the current findings on the effects of CBD on astrocyte activity, and in this way on central nervous system CNS functions, across various tested models and neuropathologies.

    The collected data shows that increased astrocyte activity is suppressed in the presence of CBD in models of ischemia, Alzheimer-like and Multiple-Sclerosis-like neurodegenerations, sciatic nerve injury, epilepsy, and schizophrenia. Moreover, CBD has been shown to decrease proinflammatory functions and signaling in astrocytes. Cannabis, cannabidiol , and epilepsy--from receptors to clinical response.

    Recreational cannabis use in adults with epilepsy is widespread. The use of cannabis for medicinal purposes is also becoming more prevalent. For this purpose, various preparations of cannabis of varying strengths and content are being used. The recent changes in the legal environment have improved the availability of products with high cannabidiol CBD and low tetrahydrocannabinol THC concentrations.

    There is some anecdotal evidence of their potential efficacy, but the mechanisms of such action are not entirely clear. The mechanism of action of CBD is less clear but is likely polypharmacological. The scientific data support the role of the endocannabinoid system in seizure generation, maintenance, and control in animal models of epilepsy.

    There are clear data for the negative effects of cannabis on the developing and mature brain though these effects appear to be relatively mild in most cases. In the past five years, an increasing number of publications have focused on the discovery of the anti-inflammatory, anti-oxidant, and neuroprotective effects of CBD.

    In particular, CBD exerts positive pharmacological effects in ischemic stroke and other chronic diseases, including Parkinson's disease, Alzheimer's disease, and rheumatoid arthritis. Importantly, CBD use does not lead to tolerance. In this review, we will discuss the therapeutic possibility of CBD as a cerebroprotective agent, highlighting recent pharmacological advances, novel mechanisms, and therapeutic time window of CBD in ischemic stroke.

    Controlled clinical trial of cannabidiol in Huntington's disease. Based on encouraging preliminary findings, cannabidiol CBD , a major nonpsychotropic constituent of Cannabis, was evaluated for symptomatic efficacy and safety in 15 neuroleptic-free patients with Huntington's Disease HD. A comparison of the effects of CBD and placebo on chorea severity and other therapeutic outcome variables, and on a Cannabis side effect inventory, clinical lab tests and other safety outcome variables, indicated no significant p greater than 0.

    Cannabis contains the psychoactive component delta9-tetrahydrocannabinol delta9-THC , and the non-psychoactive components cannabidiol CBD , cannabinol, and cannabigerol. It is well-known that delta9-THC and other cannabinoid CB1 receptor agonists are neuroprotective during global and focal ischemic injury.

    Additionally, delta9-THC also mediates psychological effects through the activation of the CB1 receptor in the central nervous system. In addition to the CB1 receptor agonists, cannabis also contains therapeutically active components which are CB1 receptor independent. The cerebroprotective action of CBD is CB1 receptor-independent, long-lasting, and has potent anti-oxidant activity.

    Cannabidiol promotes browning in 3T3-L1 adipocytes. Recruitment of the brown-like phenotype in white adipocytes browning and activation of existing brown adipocytes are currently being investigated as a means to combat obesity.

    Thus, a wide variety of dietary agents that contribute to browning of white adipocytes have been identified. The present study was designed to investigate the effects of cannabidiol CBD , a major nonpsychotropic phytocannabinoid of Cannabis sativa, on induction of browning in 3T3-L1 adipocytes.

    These data suggest possible roles for CBD in browning of white adipocytes, augmentation of lipolysis, thermogenesis, and reduction of lipogenesis. In conclusion, the current data suggest that CBD plays dual modulatory roles in the form of inducing the brown-like phenotype as well as promoting lipid metabolism.

    Thus, CBD may be explored as a potentially promising therapeutic agent for the prevention of obesity. Is there a role for cannabidiol in psychiatry? Understanding whether cannabidiol CBD is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events AEs of CBD in the treatment of schizophrenia, psychotic disorders, anxiety disorders, depression, bipolar disorder and substance-use disorders.

    We conducted a literature search in PubMed, Scielo, and Clinicaltrials. Bibliographic research yielded records. After analysis, we included six case reports and seven trials, comprising subjects. Most the studies published presented several drawbacks and did not reach statistical significance.

    We have not found evidence regarding major depressive and bipolar disorders. The level of evidence for cannabis withdrawal is B; cannabis addiction is C2; treatment of positive symptoms in schizophrenia and anxiety in social anxiety disorder is C1. Discrete or no AEs were reported. The most frequently reported AEs are sedation and dizziness. The evidence regarding efficacy and safety of CBD in psychiatry is still scarce. Further larger well-designed randomised controlled trials are required to assess the effects of CBD in psychiatric disorders.

    Could cannabidiol be used as an alternative to antipsychotics? Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects.

    Recently, the endocannabinoid system ECS has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the study of compounds that can modulate its activity for therapeutic purposes. Among them, cannabidiol CBD , a non-psychoactive component of cannabis, shows great promise for the treatment of psychosis, and is associated with fewer extrapyramidal side effects than conventional antipsychotic drugs.

    The overarching goal of this review is to provide current available knowledge on the role of the dopamine system and the ECS in schizophrenia, and to discuss key findings from animal studies and clinical trials investigating the antipsychotic potential of CBD. Cannabidiol , a Cannabis sativa constituent, as an antipsychotic drug. A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa cannabis component, induces anxiety and psychotic-like symptoms in healthy volunteers.

    These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol CBD , a cannabis constituent which is devoid of the typical effects of the plant. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs.

    The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia.

    Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated. Gene duplication and divergence affecting drug content in Cannabis sativa. Marijuana and hemp were crossed to evaluate competing models of cannabinoid inheritance and to explain the predominance of tetrahydrocannabinolic acid THCA in marijuana compared with cannabidiolic acid CBDA in hemp.

    Individuals in the resulting F2 population were assessed for differential expression of cannabinoid synthase genes and were used in linkage mapping. Genetic markers associated with divergent cannabinoid phenotypes were identified.

    Phylogenetic analysis further suggests a history of duplication and divergence affecting drug content. Marijuana is distinguished from hemp by a nonfunctional CBDA synthase that appears to have been positively selected to enhance psychoactivity.

    An unlinked QTL for cannabinoid quantity may also have played a role in the recent escalation of drug potency. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol CBD.

    The last decade has seen increasing evidence of dysfunctions in the endogenous cannabinoid system in schizophrenia and of its relationship with the typical cognitive impairment of the disorder. Studies in animal models, healthy volunteers, and psychotic patients clearly suggest an antipsychotic-like effect of cannabidiol.

    This study investigated the effects of cannabidiol on selective attention in 28 schizophrenic patients using the Stroop Color Word Test and on these patients' electrodermal responsiveness to auditive stimuli. The subjects attended two experimental sessions, the first one without the administration of drugs. In the second session the subjects were divided into three groups that received either a single dose of cannabidiol mg or cannabidiol mg or placebo.

    The three groups did not differ significantly with respect to electrodermal measures in the two experimental sessions. When the first and second sessions were compared improved performance was found in all three groups, with patients who received placebo and cannabidiol mg performing better than those who received cannabidiol mg.

    The single, acute administration of cannabidiol seems to have no beneficial effects on the performance of schizophrenic patients in the Stroop Color Word Test, although the hypothesis that chronic administration may lead to improvement cannot be disregarded. Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats. In neonatal rats, the transection of a peripheral nerve leads to an intense retrograde degeneration of both motor and sensory neurons.

    Most of the axotomy-induced neuronal loss is a result of apoptotic processes. The clinical use of neurotrophic factors is difficult due to side effects and elevated costs, but other molecules might be effective and more easily obtained.

    Among them, some are derived from Cannabis sativa. Cannabidiol CBD is the major non-psychotropic component found on the surface of such plant leaves. The present study aimed to investigate the neuroprotective potential of CBD. Thus, 2-day-old Wistar rats were divided into the following experimental groups: In line with such results, the terminal deoxynucleotidyl transferase dUTP nick end labeling reaction revealed a reduction of apoptotic cells, mostly located in the spinal cord intermediate zone, where interneurons promote sensory-motor integration.

    The present results show that CBD possesses neuroprotective characteristics that may, in turn, be promising for future clinical use. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. The aim of this study was to explore if the administration of naltrexone NTX together with cannabidiol CBD may improve the efficacy in reducing alcohol consumption and motivation rather than any of the drugs given separately. The effects of low doses of NTX 0. The combination of low doses of CBD plus NTX resulted more effective to reduce ethanol consumption and motivation to drink.

    These effects, appears to be mediated, at least in part, by 5-HT 1A receptors. This article is protected by copyright. Medical use of cannabis. The medical properties of cannabis have been known for many centuries; its first documented use dates back to BC when it was described for its hallucinogenic and pain-relieving properties.

    In the first half of the twentieth century, a number of pharmaceutical companies marked cannabis for indications such as asthma and pain, but since then its use has sharply declined, mainly due to its unpredictable effects, but also for socio-political issues. Evidence suggests an association between cannabis and schizophrenia: Additionally, the use of marijuana can trigger psychotic episodes in schizophrenic patients, and this has been ascribed to THC.

    Given the need to reduce the side effects of marketed antipsychotics, and their weak efficacy on some schizophrenic symptoms, cannabinoids have been suggested as a possible alternative treatment for schizophrenia.

    CBD, a non-psychoactive constituent of the Cannabis sativa plant, has been receiving growing attention for its anti-psychotic-like properties. Evidence suggests that CBD can ameliorate positive and negative symptoms of schizophrenia. Behavioural and neurochemical models suggest that CBD has a pharmacological profile similar to that of atypical anti-psychotic drugs and a clinical trial reported that this cannabinoid is a well-tolerated alternative treatment for schizophrenia.

    Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. The information processing appears to be deficient in schizophrenia. Prepulse inhibition PPI , which measures the inhibition of a motor response by a weak sensory event, is considered particularly useful to understand the biology of information processing in schizophrenia patients.

    Drugs that facilitate dopaminergic neurotransmission such as amphetamine induce PPI disruption in human and rodents. Clinical and neurobiological findings suggest that the endocannabinoid system and cannabinoids may be implicated in the pathophysiology and treatment of schizophrenia. Cannabidiol CBD , a non-psychotomimetic constituent of the Cannabis sativa plant, has also been reported to have potential as an antipsychotic.

    Since one possible mechanism of CBD action is the facilitation of endocannabinoid-mediated neurotransmission through anandamide, we tested the effects of an anandamide hydrolysis inhibitor URB in the amphetamine-induced PPI disruption. Pretreatment with CBD attenuated the amphetamine-disruptive effects on PPI test after systemic or intra-accumbens administration. Similar effects were also found with the inhibitor of anandamide hydrolysis.

    These results corroborate findings indicating that CBD induces antipsychotic-like effects. In addition, they pointed to the nucleus accumbens as a possible site of these effects. The increase of anandamide availability may be enrolled in the CBD effects.

    Several antiepileptic drugs AEDs , about 25, are currently clinically available for the treatment of patients with epilepsy. Despite this armamentarium and the many recently introduced AEDs, no major advances have been achieved considering the number of drug resistant patients, while many benefits have been indeed obtained for other clinical outcomes e.

    Cannabinoids have long been studied for their potential therapeutical use and more recently phytocannabinoids have been considered a valuable tool for the treatment of several neurological disorders including epilepsy.

    Among this wide class, the most studied is cannabidiol CBD considering its lack of psychotropic effects and its anticonvulsant properties. Analyse the currently available literature on CBD also in light of other data on phytocannabinoids, reviewing data spanning from the mechanism of action, pharmacokinetic to clinical evidences. Several preclinical studies have tried to understand the mechanism of action of CBD, which still remains largely not understood.

    CBD has shown significant anticonvulsant effects mainly in acute animal models of seizures; beneficial effects were reported also in animal models of epileptogenesis and chronic models of epilepsy, although not substantial. In contrast, data coming from some studies raise questions on the effects of other cannabinoids and above all marijuana. There is indeed sufficient supporting data for clinical development and important antiepileptic effects and the currently ongoing clinical studies will permit the real usefulness of CBD and possibly other cannabinoids.

    Undoubtedly, several issues also need to be addressed in the next future e. Finally, shading light on the mechanism of action and the study of other cannabinoids might represent an advantage for future developments.

    Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. Cervical cancer remains a global health related issue among females of Sub-Saharan Africa, with over half a million new cases reported each year. Different therapeutic regimens have been suggested in various regions of Africa, however, over a quarter of a million women die of cervical cancer, annually.

    This makes it the most lethal cancer amongst black women and calls for urgent therapeutic strategies. In this study we compare the anti-proliferative effects of crude extract of Cannabis sativa and its main compound cannabidiol on different cervical cancer cell lines. Results obtained indicate that both cannabidiol and Cannabis sativa extracts were able to halt cell proliferation in all cell lines at varying concentrations.

    Apoptosis was confirmed by overexpression of p53, caspase 3 and bax. In conclusion, these data suggest that cannabidiol rather than Cannabis sativa crude extracts prevent cell growth and induce cell death in cervical cancer cell lines. High dosage of cannabidiol CBD alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. The study was designed to investigate the effect of various concentrations of cannabidiol CBD in rats with chronic epilepsy.

    Behavioral measurements of convulsion following pentylenetetrazole treatment and morphological changes of the hippocampal neurons with hematoxylin and eosin staining were used to observe the epileptic behaviour.

    Immunohistochemistry was used to detect the expression levels of glial fibrillary acidic protein and inducible nitric oxide synthase iNOS in the hippocampus. The neuronal loss and astrocyte hyperplasia in the hippocampal area were also decreased.

    Thus, CBD administration inhibited the effect of pentylenetetrazole in rats, decreased the astrocytic hyperplasia, decreased neuronal damage in the hippocampus caused by seizures and selectively reduced the expression of the NR1 subunit of NMDA. Therefore, CBD exhibits an anticonvulsive effect in the rats with chronic epilepsy. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.

    We investigated the effects of cannabidiol , a non-psychoactive constituent of Cannabis sativa with anti-inflammatory properties that activates the 5-hydroxytryptamine receptor 5-HT1A, on brain and liver functions in a model of hepatic encephalopathy associated with fulminant hepatic failure induced in mice by thioacetamide.

    Neurological and motor functions were evaluated 2 and 3 days, respectively, after induction of hepatic failure, after which brains and livers were removed for histopathological analysis and blood was drawn for analysis of plasma liver enzymes. In a separate group of animals, cognitive function was tested after 8 days and brain 5-HT levels were measured 12 days after induction of hepatic failure.

    Similarly, decreased motor activity in thioacetamide-treated mice was partially restored by cannabidiol. Increased plasma levels of ammonia, bilirubin and liver enzymes, as well as enhanced 5-HT levels in thioacetamide-treated mice were normalized following cannabidiol administration.

    Likewise, astrogliosis in the brains of thioacetamide-treated mice was moderated after cannabidiol treatment. Therefore, the effects of cannabidiol may result from a combination of its actions in the liver and brain. Hepatic encephalopathy is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We investigated the effects of cannabidiol , a non-psychoactive constituent of Cannabis sativa with anti-inflammatory properties that activates the 5-hydroxytryptamine receptor 5-HT 1A , on brain and liver functions in a model of hepatic encephalopathy associated with fulminant hepatic failure induced in mice by thioacetamide.

    Female Sabra mice were injected with either saline or thioacetamide and were treated with either vehicle or cannabidiol. Neurological and cognitive functions were severely impaired in thioacetamide-treated mice and were restored by cannabidiol. Cannabidiol restores liver function, normalizes 5-HT levels and improves brain pathology in accordance with normalization of brain function. Report of a parent survey of cannabidiol -enriched cannabis use in pediatric treatment-resistant epilepsy.

    Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol -enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol -enriched cannabis to treat their child's seizures.

    Nineteen responses met the following inclusion criteria for the study: Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox-Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs AEDs tried before using cannabidiol -enriched cannabis was Other beneficial effects included increased alertness, better mood, and improved sleep.

    Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol -enriched cannabis as a treatment for their children with treatment-resistant epilepsy. Because of the increasing number of states that allow access to medical cannabis, its use will likely be a growing concern for the epilepsy community.

    Safety and tolerability data for cannabidiol -enriched cannabis use among children are not available. Objective measurements of a standardized preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.

    In recent research, orally administered cannabidiol CBD showed a relatively high incidence of somnolence in a pediatric population. To gain a better understanding of quantitative exposure, we completed an in vitro study by evaluating the formation of psychoactive cannabinoids when CBD is exposed to simulated gastric fluid SGF. Linearity was demonstrated for each component over the concentration range used in this study. Samples were analyzed using chromatography with UV and mass spectrometry detection.

    The first-order kinetics observed in this study allowed estimated levels to be calculated and indicated that the acidic environment during normal gastrointestinal transit can expose orally CBD-treated patients to levels of THC and other psychoactive cannabinoids that may exceed the threshold for a physiological response.

    Delivery methods that decrease the potential for. Cannabidiol -treated rats exhibited higher motor score after cryogenic spinal cord injury. Cannabidiol CBD , a non-psychoactive constituent of cannabis, has been reported to induce neuroprotective effects in several experimental models of brain injury. We aimed at investigating whether this drug could also improve locomotor recovery of rats submitted to spinal cord cryoinjury.

    Rats were distributed into five experimental groups. The extent of injury was evaluated by hematoxylin-eosin histology and FosB expression. Cryogenic lesion of the spinal cord resulted in a significant motor deficit. Cannabidiol -treated rats exhibited a higher Basso, Beattie, and Bresnahan locomotor score at the end of the first week after spinal cord injury: Moreover, at this moment there was a significant reduction in the extent of tissue injury and FosB expression in the ventral horn of the spinal cord.

    The present study confirmed that application of liquid nitrogen to the spinal cord induces reproducible and quantifiable spinal cord injury associated with locomotor function impairments. Cannabidiol improved locomotor functional recovery and reduced injury extent, suggesting that it could be useful in the treatment of spinal cord lesions. Cannabidiol regulation of emotion and emotional memory processing: Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival.

    Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively.

    These disorders are associated with abnormally persistent emotional memories and inadequate treatment, often leading to symptom relapse. Studies show that cannabidiol , the main non-psychotomimetic phytocannabinoid found in Cannabis sativa, reduces anxiety via 5-HT 1A and indirect cannabinoid receptor activation in paradigms assessing innate responses to threat. There is also accumulating evidence from animal studies investigating the effects of cannabidiol on fear memory processing indicating that it reduces learned fear in paradigms that are translationally relevant to phobias and post-traumatic stress disorder.

    Cannabidiol does so by reducing fear expression acutely and by disrupting fear memory reconsolidation and enhancing fear extinction, both of which can result in a lasting reduction of learned fear. Recent studies have also begun to elucidate the effects of cannabidiol on drug memory expression using paradigms with translational relevance to addiction. The findings suggest that cannabidiol reduces the expression of drug memories acutely and by disrupting their reconsolidation.

    Here, we review the literature demonstrating the anxiolytic effects of cannabidiol before focusing on studies investigating its effects on various fear and drug memory processes. Understanding how cannabidiol regulates emotion and emotional memory processing may eventually lead to its use as a treatment for anxiety-related and substance abuse disorders.

    Linked Articles This article is part of a themed section on Pharmacology of Cognition: To view the other articles in this section visit. Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells. Clostridium difficile toxin A is responsible for colonic damage observed in infected patients.

    Drugs able to restore Clostridium difficile toxin A-induced toxicity have the potential to improve the recovery of infected patients. The purpose of this study was to evaluate a the anti-apoptotic effect and b the mechanisms by which cannabidiol protects mucosal integrity in Caco-2 cells exposed to Clostridium difficile toxin A.

    Cytotoxicity assay, transepithelial electrical resistence measurements, immunofluorescence analysis and immunoblot analysis were performed in the different experimental conditions. Clostridium difficile toxin A significantly decreased Caco-2 cells' viability and reduced transepithelial electrical resistence values and RhoA guanosine triphosphate GTP , bax, zonula occludens-1 and occludin protein expression, respectively.

    All these effects were significantly and concentration-dependently inhibited by cannabidiol , whose effects were completely abolished in the presence of the cannabinoid receptor type 1 CB1 antagonist, AM Cannabidiol improved Clostridium difficile toxin A-induced damage in Caco-2 cells, by inhibiting the apoptotic process and restoring the intestinal barrier integrity, through the involvement of the CB1 receptor.

    However, further elucidation of the channel properties and physiological role of TRPV2 have been hindered by the lack of selective pharmacological tools as well as by the species-dependent differences in the activation of this channel. In the present study, we have used cell-based calcium mobilization and electrophysiological assays to identify and characterize several novel cannabinoid TRPV2 agonists.

    We also demonstrated that cannabidiol evoked a concentration-dependent release of calcitonin gene-related peptide CGRP from cultured rat dorsal root ganglion neurons in a cannabinoid receptor- and TRPV1-independent manner.

    Moreover, the cannabidiol -evoked CGRP release depended on extracellular calcium and was blocked by the nonselective TRP channel blocker, ruthenium red. We further provide evidence through the use of small interfering RNA knockdown and repetitive stimulation studies, to show that cannabidiol -evoked CGRP release is mediated, at least in part, by TRPV2. Together, these data suggest not only that TRPV2 may comprise a mechanism whereby cannabidiol exerts its clinically beneficial effects in vivo, but also that TRPV2 may constitute a viable, new drug target.

    Anxiety and sleep disorders are often the result of posttraumatic stress disorder and can contribute to an impaired ability to focus and to demonstration of oppositional behaviors.

    These symptoms were present in our patient, a ten-year-old girl who was sexually abused and had minimal parental supervision as a young child under the age of five. Pharmaceutical medications provided partial relief, but results were not long-lasting, and there were major side effects.

    A trial of cannabidiol oil resulted in a maintained decrease in anxiety and a steady improvement in the quality and quantity of the patient's sleep. Cannabidiol oil, an increasingly popular treatment of anxiety and sleep issues, has been documented as being an effective alternative to pharmaceutical medications. This case study provides clinical data that support the use of cannabidiol oil as a safe treatment for reducing anxiety and improving sleep in a young girl with posttraumatic stress disorder.

    Cannabidiol in patients with treatment-resistant epilepsy: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish whether addition of cannabidiol to existing anti-epileptic regimens would be safe, tolerated, and efficacious in children and young adults with treatment-resistant epilepsy.

    In this open-label trial, patients aged years with severe, intractable, childhood-onset, treatment-resistant epilepsy, who were receiving stable doses of antiepileptic drugs before study entry, were enrolled in an expanded-access programme at 11 epilepsy centres across the USA. The primary objective was to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median percentage change in the mean monthly frequency of motor seizures at 12 weeks.

    The efficacy analysis was by modified intention to treat. Comparisons of the percentage change in frequency of motor seizures were done with a Mann-Whitney U test. The remaining patients had intractable epilepsies of different causes and type. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Background Cannabidiol CBD is a naturally occurring constituent of the marijuana plant. In the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is currently being explored for numerous disease conditions e.

    Despite its status, there are no well-controlled data available regarding its abuse liability. Participants received one dose combination across 8 once-weekly outpatient sessions 7.

    The primary findings on the drug interaction effects were previously reported Haney et al. The present study is a secondary analysis of the data to examine the abuse liability profile of oral cannabidiol , , mg in comparison to oral placebo and active smoked marijuana 5. Results Active marijuana reliably produced abuse-related subjective effects e. Conclusions Overall, CBD did not display any signals of abuse liability at the doses tested and these data may help inform U.

    Cannabidiol CBD has been traditionally used in Cannabis -based preparation, however historically, it has received far less interest as a single drug than the other components of Cannabis. Currently, CBD generates considerable interest due to its beneficial neuroprotective, antiepileptic, anxiolytic, antipsychotic, and anti-inflammatory properties.

    Therefore, the CBD scaffold becomes of increasing interest for medicinal chemists. This review provides an overview of the chemical structure of natural and synthetic CBD derivatives including the molecular targets associated with these compounds.

    A clear identification of their biological targets has been shown to be still very challenging. Cannabidiol for the treatment of cannabis withdrawal syndrome: Cannabis withdrawal in heavy users is commonly followed by increased anxiety, insomnia, loss of appetite, migraine, irritability, restlessness and other physical and psychological signs.

    Tolerance to cannabis and cannabis withdrawal symptoms are believed to be the result of the desensitization of CB1 receptors by THC. Daily symptom assessments demonstrated the absence of significant withdrawal, anxiety and dissociative symptoms during the treatment.

    CBD can be effective for the treatment of cannabis withdrawal syndrome. Cannabidiol CBD has been traditionally used in Cannabis-based preparation, however historically, it has received far less interest as a single drug than the other components of Cannabis. Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required.

    Cannabidiol CBD , the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model, we examined the effect of chronic CBD treatment on cognition and social interaction.

    Body weight, food and water intake was measured weekly. The Novel Object Recognition and rewarded T-maze alternation tests assessed recognition and working memory, respectively, and the social interaction test assessed sociability. In conclusion, chronic CBD administration can attenuate the social interaction and cognitive deficits induced by prenatal poly I: These novel findings present interesting implications for potential use of CBD in treating the cognitive deficits and social withdrawal of schizophrenia.

    Cannabidiol -2',6'-dimethyl ether as an effective protector of lipoxygenase-mediated low-density lipoprotein oxidation in vitro. We have recently reported that cannabidiol -2',6'-dimethyl ether CBDD is a selective and potent inhibitor of LOX-catalyzed linoleic acid oxygenation Takeda et al. These studies establish CBDD as both an important experimental tool for characterizing LOX-mediated ox-LDL formation, and as a potentially useful therapeutic agent for treatment of atherosclerosis.

    Oxidative stress with reactive oxygen species generation is a key weapon in the arsenal of the immune system for fighting invading pathogens and to initiate tissue repair. If excessive or unresolved, however, immune-related oxidative stress can initiate further increasing levels of oxidative stress that cause organ damage and dysfunction.

    Targeting oxidative stress in these various diseases therapeutically has proven more problematic than first anticipated given the complexities and perversity of both the underlying disease and the immune response. However, growing evidence suggests that the endocannabinoid system, which includes the CB1 and CB2 G protein-coupled receptors and their endogenous lipid ligands, may be an area that is ripe for therapeutic exploitation.

    In this context, the related nonpsychotropic cannabinoid cannabidiol , which may interact with the endocannabinoid system, but has actions that are distinct, offers promise as a prototype for anti-inflammatory drug development. This review discusses recent studies suggesting that cannabidiol may have utility in treating a number of human diseases and disorders now known to involve activation of the immune system and associated oxidative stress, as a contributor to their etiology and progression.

    In the last years, mesenchymal stromal cells MSCs from oral tissues have received considerable interest in regenerative medicine since they can be obtained with minimal invasive procedure and exhibit immunomodulatory properties. This study was aimed to investigate whether in vitro pre-treatment of MSCs obtained from human gingiva hGMSCs with Cannabidiol CBD , a cannabinoid component produced by the plant Cannabis sativa, may promote human gingiva derived MSCs to differentiate toward neuronal precursor cells.

    Genes involved in DNA replication, cell cycle, proliferation, and apoptosis were regulated. Moreover, genes associated with the biological process of neuronal progenitor cells NCPs proliferation, neuron differentiation, neurogenesis, and nervous system development were significantly modulated. From our results, we hypothesize that human gingiva-derived MSCs conditioned with CBD could represent a valid method for improving the hGMSCs phenotype and thus might be a potential therapeutic tool in the treatment of neurodegenerative diseases.

    Diminished gray matter in the hippocampus of cannabis users: Chronic cannabis use has been associated with memory deficits and a volume reduction of the hippocampus, but none of the studies accounted for different effects of tetrahydrocannabinol THC and cannabidiol CBD. Using a voxel based morphometry approach optimized for small subcortical structures DARTEL gray matter GM concentration and volume of the hippocampus were measured in 11 chronic recreational cannabis users and 13 healthy controls, and correlated with THC and CBD from hair analyses.

    GM volume was calculated by modulating VBM using Jacobian determinants derived from the spatial normalization. Lower volume in the right hippocampus in chronic cannabis users was corroborated.

    This confirms existing preclinical and clinical results. As a possible mechanism the influence of cannabinoids on hippocampal neurogenesis is suggested.

    Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. We have previously shown that the prophylactic treatment with cannabidiol CBD reduces inflammation in a model of acute lung injury ALI. In this work we analyzed the effects of the therapeutic treatment with CBD in mice subjected to the model of lipopolysaccharide LPS -induced ALI on pulmonary mechanics and inflammation.

    The results show that CBD decreased total lung resistance and elastance, leukocyte migration into the lungs, myeloperoxidase activity in the lung tissue, protein concentration and production of pro-inflammatory cytokines TNF and IL-6 and chemokines MCP-1 and MIP-2 in the bronchoalveolar lavage supernatant. Thus, we conclude that CBD administered therapeutically, i. Therefore the present and previous data suggest that in the future cannabidiol might become a useful therapeutic tool for the attenuation and treatment of inflammatory lung diseases.

    Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Cannabidiol CBD , a non-psychotomimetic compound of the Cannabis sativa, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects.

    We have recently reported that Spontaneously Hypertensive Rats SHRs present a deficit in social interaction that is ameliorated by atypical antipsychotics. In addition, SHRs present a hyperlocomotion that is reverted by typical and atypical antipsychotics, suggesting that this strain could be useful to study negative symptoms modeled by a decrease in social interaction and positive symptoms modeled by hyperlocomotion of schizophrenia as well as the effects of potential antipsychotics drugs.

    At the same time, an increase in social interaction in control animals similar to that induced by benzodiazepines is used to screen potential anxiolytic drugs. However, the hyperlocomotion and the deficit in social interaction displayed by SHRs were not altered by any dose of CBD. Our results do not support an antipsychotic property of cannabidiol on symptoms-like behaviors in SHRs but reinforce the anxiolytic profile of this compound in control rats.

    The legal status of cannabis marijuana and cannabidiol CBD under U. In the United States, federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers.

    Many of these artisanal products are sold in dispensaries or over the internet. Hydroxyapatite density was calculated hind paw. Along with OA development, the joint with the specimen. Statistical analysis P , 0. Again, there was no hypersensitivity on the Changes in weight distribution and joint pain in the MIA-treated vs contralateral hind paw. Unless stated significant, and long-lasting decreases on days 7 and 14, otherwise, the data were analyzed using a one-way analysis of respectively.

    Time course and concentration relationship of the effect of intra-articular injection of MIA 0. MIA injection resulted in a concentration-dependent weight-bearing impairment recorded as the difference in hind limb dynamic weight bearing in both weight in grams and surface in square millimeters ratio ipsilateral—contralateral recordings. Additionally, pressure application measurements of knee joint withdrawal thresholds detected a dose-dependent hypersensitivity. A statistical analysis was performed using a one-way analysis of variance followed by Bonferroni post hoc test.

    The values with P , 0. The values are the means 6 SEM. After returning to normal activity levels, the OA rats bearing asymmetry is biphasic, with the asymmetry slightly became progressively hypersensitive to pressure applied to the correcting at the day 10 time point but returning at day N fluctuations reflected the fact that the XMT bone microstructure image at day 14 had not yet changed. It can be assumed that bone density was decreasing, but the structure had not changed at this time point.

    Expression of atf-3 and il-6 on the lumbar L4—L6 dorsal root ganglia of the rats exposed to MIA injection As a marker of nerve injury and proinflammatory cytokines Figure 2. The ipsilateral pressure application measurement of limb withdrawal catabolic in general produced by joint tissue and released into threshold of saline and MIA-treated rats over a day study.

    MIA injection the synovial fluid, the mRNA levels of activating transcription resulted in a biphasic decrease of the withdrawal threshold of the injected paw factor 3 atf-3 and interleukin 6 il-6 were quantified by real-time with a chronic phase beginning approximately 12 days after the MIA injection. The OA animals showed a significant increase in atf-3 expression, which was different from the control animals as early as day 2 from 1 6 changes between LWT readouts from day 14 to day 28, day 14 0.

    The atf-3 expression declined OMDM to minimize the suffering of the animals. Indeed, slightly until day 14, although it was significantly higher than the consistent with literature data,9,26 day 14 after MIA injection baseline expression observed in the control animals Significant differences between the ipsilateral and contralateral sides were also noted for days 2 and MIA progression and bone destruction A significant imbalance in il-6 expression levels was observed X-ray microtomographic images of bone microstructure repre- in the osteoarthritic rats Fig.

    The measurement of bone microstructure the contralateral DRG of the OA animals at all time points studied was performed using the known histomorphometry parameters P. On day 2, an number Th. N , which are based on binarized images. The results are presented noted on day 7. The unilateral il-6 upregulation was observed in Table 1. Referenced VOI 3 3 voxels 3. An increase in the bone material We next determined the changes in cnr1, trpv1, and faah mRNA because of the compacting of destroyed trabecules was levels because they represent primary targets for the piperazinyl observed.

    The contralateral sections of the lumbar DRG of the OA rats are shown thickness of the trabecules increased, whereas arthritis was not in Fig. A reverse pattern characterized day This increase was the trabecular thickness decreased, whereas the trabecules observed at all 3 time points tested upregulation from 1 6 0. The HAD analysis gave the following results: HADday 0 5 there was an increase observed on the contralateral side as well 1.

    Significantly higher cnr1 transcript levels 1. The BMD estimated using HAD at day 14 was were present on days 7 and 14 in the ipsilateral compared with decreasing, most likely as a result of a reduction in bone mineral the contralateral side. X-ray microtomography—based 3-dimensional visualization of the knee joint samples during the development of osteoarthritis pain in the iodoacetate- injected rats at days 0, 14, and The amount of faah 3.

    Immunohistochemical colocalization of in the iodoacetate-injected rats at days 0, 14, and N, trabecular number; Tb. Results of the quantitative polymerase chain reaction analysis of atf-3 A and il-6 B gene expression levels in the L4—L6 dorsal root ganglia during the C development of osteoarthritis pain in MIA-treated rats. Samples were collected 2, 7, and 14 days after osteoarthritis induction. Data are presented as the means 6 SEM and represent the normalized averages derived from 4 to 6 samples for each group.

    The results are presented as a fold change normalized to the expression of a reference gene, hprt1, compared with the intact animals. A Statistical analysis was performed using a one-way analysis of variance followed by Bonferroni post hoc test.

    Values with P , 0. The staining profiles for the controls healthy rats were similar data not shown. TRPV12CB11 cells did not change in our experimental setting Samples were collected 2, 7, and 14 days after osteoarthritis induction. These data suggest values with P , 0. The effects of systemic OMDM administration on treatment groups: Osteoarthritis was induced in the rats by the intra-articular The application of vehicle had no significant effect on the pain injection of 3 mg of MIA.

    The animals were allowed to recover for response as measured in the LWT. Intriguingly, compared with the vehicle, the effects of OMDM at doses of 2. A1 A2 In a subsequent study, rats n 5 40 were randomly assigned to one of 5 treatment groups: Each group consisted of n 5 8 animals. However, the molar doses 2. Discussion The high incidence of OA in the elderly population, along with the increasing age of the general population, indicates that the number of patients suffering from pain associated with this condition will increase and emphasizes the need to validate preclinical models of OA that can be used to assess both the E factors contributing to OA pain and the disease-modifying effects of potential therapeutics.

    An intra-articular injection of 3 mg of MIA induced a sustained decrease in hind limb weight bearing and an increase in joint hypersensitivity. In a human clinical population, OA is not suspected until there has been a significant disease progression, at which time the disease is associated with joint dysfunction and pain.

    In this study, pain behavior associated with intra-articular MIA injection was bi- phasic, with the initial phase lasting approximately 8 days and the chronic phase beginning at day As evidenced by XMT, no bone destruction was observed until the chronic phase, further supporting the fact that the majority of damage to articular tissue Figure 6. Each column represents the mean of at least 4 areas A1-D1 and contralateral A2-D2 to injection.

    The images represent the counted by 2 observers who were blinded to the study. No statistical significance P , 0. Scale bar 5 mm. This mirrors the clinical situation in which patients report pain with no severe joint damage present. X-ray microtomography demonstrated that intra- articular MIA induced significant alterations in the subchondral bone; additionally, in the same regions of the joint where the changes in the subchondral bone were observed, cartilage loss might also occur.

    Indeed, IL-6 levels significantly increased as early as 2 days after MIA injection, which may promote OA development and modulate the effects of cytokines such as IL-1b, tumor necrosis factor a, IL or IL, which also promote tissue damage. Another study suggested a similarity between OA and neuropathic pain. Consequently, in this study, increased transcripts of atf-3 in the L4—L6 DRG might be indicative of neuronal FAAH damage73 and imply that the intra-articular injection of MIA is associated with early neuropathy, as demoinstrated by the fact that IL-6 levels were not significantly different from control levels, the cytokine was instead upregulated at day Indeed, IL-6 is not exclusively involved in the inflammatory response and might also participate in the induction of mechanical hypersensitivity and hyperalgesic priming in different types of D1 D2 arthritis.

    Osteoarthritis might be considered as inflammatory disorder, but the resolution of inflammation at the later time merge points with histological changes within the bone and the lack of correlation between atf-3 and il-6 transcripts seem to rule out this link.

    A further assessment of atf-3 expression at later time points would elucidate whether the pathological changes observed herein fluctuate with time. Studies in animal OA models have revealed enhanced levels of endocannabinoids in the spinal cord and associated elevations in protein levels of endocannabinoid biosynthetic E enzymes.

    Different subpopulations of neurons were immunoreactive Figure 7. Each column represents the mean of at least 4 areas counted by 2 induced osteoarthritis. The images represent the distribution of was found. Indeed, throughout the time course of this study, OMDM exhibited a significant reversal of joint hypersensitivity. OMDM was effective only at the lowest tested dose, and this could be because the full inhibition of Figure 9.

    However, However, an alteration in the DRG at day 2 was observed. In fact, we observed profile Supplementary Fig. Nonpsychoactive cannabinoids, In summary, the model of intra-articular MIA injections provides such as cannabidiol CBD and HU, can reduce joint a preclinical tool in which consistent pain readouts are inhibited by damage and inflammation in murine collagen-induced arthri- OMDM, a synthetic compound that inhibits FAAH and tis,47,70 suggesting their potential as therapeutic agents for antagonizes TRPV1.

    Our results may lead to an innovative arthritis. The presence of the endocannabinoid system in the pharmacotherapic strategy for OA. Accordingly, preventing AEA Conflict of interest statement breakdown in neuronal and non-neuronal cells was shown to produce beneficial effects for the treatment of osteoarthritic pain The authors have no conflicts of interest to declare.

    OA pain in a randomized placebo-controlled phase II clinical trial. Accepted 2 February [18] DiMarzo V. Inhibitors of endocannabinoid breakdown for pain: Available online 20 February [19] Donaldson LF.

    Trends Neurosci ; Mechanistic and pharmacological characterization of PF Biocybern Biomed Eng Inhibition of fatty acid amidohydrolase, the enzyme responsible ; The cannabinomimetic arachidonyl arachidonoyl-serotonin. J Enzyme Inhib Med Chem ; Br J Pharmacol ; Pressure application measurement and dorsal horn nociceptive neuron hyperexcitability.

    J Neurosci Methods ; August , Singapore. Springer Berlin Heidelberg, Repeated administration of vanilloid receptor — Image-based finite element J Pharmacol Exp Ther ; Cartilage homeostasis in health and rheumatic editor.

    Arthritis Res Ther ; Molecular targets for response study of loss of mobility, morphology, and biochemistry. Biochem Biophys Res Commun ; Short-term efficacy of osteolytic and osteoblastic model of bone cancer. Clin J Pain ; Eur J Pain ; Weight bearing as a measure of disease progression J Rheumatol ; Spinal and peripheral mechanisms of cannabinoid — Bone remodelling in osteoarthritis.

    Chem Phys Lipids ; A [1-isoquinolinyl 4-trifluoromethyl-benzyl - of neuropathic pain. Involvement of injury in rats. J Pharmacol Exp Ther ; An efficient response to two environment pollutants: Supersensitivity to anandamide and enhanced pain due to osteoarthritis of the knee.

    J Med Chem ;

    Cannabidiol (CBD) induces functional Tregs in response to low-level T cell mechanical allodynia, but reduced peripheral nerve block-induced CPP, and the rats ( g) by intra-articular injection of sodium monoiodoacetate (MIA; 3 mg). Prophylactic CBD treatment prevented the later development of pain and. Cannabidiol Modulates the Expression of Alzheimer's Disease-Related mechanical allodynia, but reduced peripheral nerve block-induced CPP, and the rats ( g) by intra-articular injection of sodium monoiodoacetate (MIA; 3 mg). The therapeutic and prophylactic effects of peripheral CBD ( μg) were. (28%), alcoholic neuropathy (%), sodium monoiodoacetate (MIA – %) and neuropathic pain induced by paclitaxel (%). The opioids caused by tumours compressing peripheral nerves, the toxins used in . Cannabidiol/ cannabino .. icines seeking treatment, cure and prevention of diseases, is.

    1. Introduction


    Add Comment